OCA
ELEV

Octagon Capital Advisors’s Elevation Oncology ELEV Stock Holding History

Octagon Capital Advisors’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-747,000
Closed -$2.02M – 47
2024
Q2 		$2.02M Buy
+747,000
New +$2.81M 0.32% 37

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Octagon Capital Advisors's ELEV Position: Q3 2024 in Review

Octagon Capital Advisors sold out of Elevation Oncology (ELEV) in Q3 2024, closing a stake of 747,000 shares — an estimated $2.02M sold.

Octagon Capital Advisors first reported a position in ELEV in Q2 2024 and held it in 1 quarter. The position peaked at $2.02M in Q2 2024. 68 funds tracked by Wall St. Rank hold ELEV as of Q3 2024.

  • Octagon Capital Advisors reported no remaining Elevation Oncology position as of Q3 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 747,000 Elevation Oncology shares in Q3 2024, an estimated $2.02M.
  • Octagon Capital Advisors first reported a position in Elevation Oncology in Q2 2024 and held it in 1 quarter.
  • Octagon Capital Advisors's Elevation Oncology position peaked at $2.02M in Q2 2024.
  • 68 funds tracked by Wall St. Rank held Elevation Oncology as of Q3 2024.

Based on Octagon Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.